Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Autus Valve Pivotal Study

A legfontosabb adatok

Ki végzi
Edwards Lifesciences
Hol
Ann Arbor, Atlanta, Aurora, Boston, Chicago, Columbus, Durham, Los Angeles, New York, Philadelphia, Salt Lake City és Seattle (Egyesült Államok)Mind a 12 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
62 fő vett részt
Kezdés
2024. febr. 5.
Várható befejezés
2036. febr. 5.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Pulmonary Valve Replacement Surgery
A regiszteradat frissítve
2026. október 20.

Ki vehet részt

Életkor
18 hónap – 16 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (29)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study
  • Age 18 months to 16 years
  • Male or female
  • Subject has a native or repaired right ventricular outflow tract
  • Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon)
  • Subject has at least one of the following echocardiographic findings:; Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg); Moderate or greater pulmonary regurgitation; Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation
  • Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter)
  • Subject and parent/legal representative, where appropriate, are willing to provide informed written consent
  • Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits

Ki nem vehet részt

  • Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses
  • Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening
  • Candidates will be excluded from the study if any of the following conditions are met:
  • Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg)
  • Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
  • Subject has active endocarditis or a history of infective endocarditis
  • Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs
  • Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes
  • Subject needs emergency cardiac or vascular surgery or intervention
  • Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease
  • Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  • Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L)
  • Subject has thrombocytopenia (defined as platelet count <50 x 103/µL
  • Subject requires valve replacement in a non-pulmonary position
  • Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years)
  • Subject has pulmonary atresia and major aortopulmonary collaterals
  • Subject has significant peripheral pulmonary artery stenosis
  • Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years
  • Subject or parent/legal representative refuses blood transfusions
  • Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures

Helyszínek itt: Egyesült Államok

  • University of Michigan/Mott Children's HospitalAnn Arbor, Egyesült Államok
  • Children's Healthcare of AtlantaAtlanta, Egyesült Államok
  • Children's Hospital ColoradoAurora, Egyesült Államok
  • Boston Children's HospitalBoston, Egyesült Államok
  • Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, Egyesült Államok
  • Nationwide Children's HospitalColumbus, Egyesült Államok
  • Duke UniversityDurham, Egyesült Államok
  • Children's Hospital Los AngelesLos Angeles, Egyesült Államok
  • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's HospitalNew York, Egyesült Államok
  • Children's Hospital of PhiladelphiaPhiladelphia, Egyesült Államok
  • University of Utah - Intermountain Primary Children's HospitalSalt Lake City, Egyesült Államok
  • Seattle Children's HospitalSeattle, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

A teljes eredeti leírásKevesebb

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

A vizsgálat csoportja

  • Autus Valve ArmA vizsgált kezelés

    Pulmonary Valve Replacement Surgery with the Autus Valve

    Kezelés: Pulmonary Valve Replacement Surgery

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Pivotal Study
A regiszteradat frissítve
2026. október 20.